- Home
- FNA vs OCS Comparison
FNA vs OCS Comparison
Compare FNA & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNA
- OCS
- Stock Information
- Founded
- FNA 2010
- OCS 2003
- Country
- FNA United States
- OCS Switzerland
- Employees
- FNA N/A
- OCS N/A
- Industry
- FNA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- FNA Health Care
- OCS Health Care
- Exchange
- FNA Nasdaq
- OCS Nasdaq
- Market Cap
- FNA 910.9M
- OCS 916.3M
- IPO Year
- FNA 2021
- OCS N/A
- Fundamental
- Price
- FNA $13.03
- OCS $21.41
- Analyst Decision
- FNA Buy
- OCS Strong Buy
- Analyst Count
- FNA 7
- OCS 5
- Target Price
- FNA $15.20
- OCS $28.80
- AVG Volume (30 Days)
- FNA 2.4M
- OCS 63.6K
- Earning Date
- FNA 03-03-2025
- OCS 03-17-2025
- Dividend Yield
- FNA N/A
- OCS N/A
- EPS Growth
- FNA N/A
- OCS N/A
- EPS
- FNA N/A
- OCS N/A
- Revenue
- FNA $244,995,000.00
- OCS $1,027,571.00
- Revenue This Year
- FNA $19.14
- OCS $7.98
- Revenue Next Year
- FNA $14.16
- OCS $853.39
- P/E Ratio
- FNA N/A
- OCS N/A
- Revenue Growth
- FNA 18.16
- OCS N/A
- 52 Week Low
- FNA $4.65
- OCS $10.55
- 52 Week High
- FNA $13.59
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- FNA 74.47
- OCS 52.07
- Support Level
- FNA $10.11
- OCS $20.95
- Resistance Level
- FNA $13.08
- OCS $21.86
- Average True Range (ATR)
- FNA 0.04
- OCS 0.56
- MACD
- FNA -0.09
- OCS -0.26
- Stochastic Oscillator
- FNA 35.00
- OCS 56.18
About FNA Paragon 28 Inc.
Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, Charcot, fracture fixation, hallux valgus, hammertoe, and flat foot. The company's suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. Geographically the company generates the majority of its revenue from the United States.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.